Company Overview and News

Stocks' Last Cheap Sector

2018-10-13 seekingalpha
Gold miners’ stocks are the last cheap sector in these entire lofty stock markets. They’ve languished deeply out of favor for years as investors forgot portfolio diversification.

SPX to Report Third Quarter 2018 Financial Results on November 1st

2018-10-11 globenewswire
CHARLOTTE, N.C., Oct. 11, 2018 (GLOBE NEWSWIRE) -- SPX Corporation (NYSE:SPXC) announced today that it will release its third quarter 2018 financial results after market close on Thursday, November 1, 2018.

Market Volatility Bulletin: Light CPI Provides What May Turn Out To Be Short-Lived Support To Stocks

2018-10-11 seekingalpha
The pain of yesterday’s sell off in US assets reverberated across the globe. CPI is providing fodder for what may be a short-lived rally.

Manitex International, Inc. Appoints Laura R. Yu as Senior Vice President and Chief Financial Officer

2018-10-10 globenewswire
BRIDGEVIEW, Ill., Oct. 10, 2018 (GLOBE NEWSWIRE) -- Manitex International, Inc. (NASDAQ:MNTX), a leading international provider of cranes and specialized industrial equipment, today announced that Laura R. Yu has been named Senior Vice President and Chief Financial Officer of Manitex International, Inc., effective October 15, 2018.

The Internal Correction Accelerates

2018-10-05 seekingalpha
Stocks took a dive on Thursday as the extraordinary selling pressure in rate-sensitive securities finally spilled over into the rest of the market. In today’s commentary, we’ll discuss the prospects for a sharp but short-lived pullback in the major averages in the coming days, followed by a confirmed bottom by mid-month.

Fed's Quantitative Tightening Is Bull's Death Knell

2018-09-29 seekingalpha
The Fed’s unprecedented quantitative-tightening campaign to unwind trillions of dollars of QE is just hitting terminal velocity. That’s incredibly bearish for bubble-valued stock markets late in a monster bull.

A Rate-Sensitive Stock Market

2018-09-26 seekingalpha
With October beckoning, analysts and investors are increasingly talking about the possibility of an autumn correction. It’s hard to argue with this logic since the S&P 500 Index has rallied steadily since July, has barely had move greater than 1% in either direction recently, and is once again becoming distended from its underlying 200-day moving average. As we’ll discuss here, all of these technical factors, combined with the market’s vulnerability to rising Treasury yields, will likely mean we finally see a pullback by the early part of October.

Market Volatility Bulletin: Markets Shrug Off 'Trade War' Fears, September VX Futures Expire Tomorrow Morning

2018-09-18 seekingalpha
Cyclicals act as a tailwind in today's markets, and spot VIX is on the back foot just before Sep VX expiration.

Auto Replacement Parts Outlook: Long Growth Path in Front

2018-09-13 zacks
Consumer’s growing awareness of vehicle servicing and preventive maintenance has led to improved vehicle longevity. Presently, the average age of vehicles on the road is 11.5 years and is augmenting at a steady pace. This surging demand for replacement parts to maximize lifetime value of old vehicles is driving revenues and opening up huge growth prospects for companies offering such automotive replacement parts.

Don't Just Play The Game. Read It

2018-09-04 seekingalpha
Like the game of basketball, the market develops certain patterns that frequently repeat and which should be read when playing the game.

Asset Prices Need Debit To Continue

2018-08-30 seekingalpha
Last week we talked about the WSJ article called the Jocks vs. the Nerds, the article discussed the migration of trading and financial markets from open outcry big boy fraternity clubs and Rolex wielding, heavy cell phone Wall Street traders toward a geekier quant PhD programming algorithmic style of today. The illustration that came with the article was great, credit Scott Anderson with a masterful piece, with a Gordon Gekko banker shirt and suspenders topped off with a heavy Motorola first edition battery phone to a blue tooth, iPad, zipper vest wearing programmer trying to look cool.

SPX to Present at the Midwest IDEAS Investor Conference on August 30th in Chicago

2018-08-27 globenewswire
CHARLOTTE, N.C., Aug. 27, 2018 (GLOBE NEWSWIRE) -- SPX Corporation (NYSE:SPXC) announced today that Paul Clegg, Vice President, Investor Relations and Communications, will present at the Midwest IDEAS Conference on Thursday, August 30th, 2018, in Chicago, IL. SPXC’s presentation will begin at 10:40 am CT, will be webcast live and may be accessed at the conference website,, or in the Investor Relations section of SPX’s website www.

RPT-BUZZ- U.S. stocks weekly: Checking the compass

2018-08-20 reuters
** This as the Nasdaq Composite tries to catch its breadth and a Nasdaq volatility measure remains less than cooperative

BUZZ- U.S. stocks weekly: Checking the compass

2018-08-17 reuters
** This as the Nasdaq Composite tries to catch its breadth and a Nasdaq volatility remains less than cooperative

Turkish Lira Plunge Signals Warning Signs?

2018-08-16 seekingalpha
What an interesting week, to say the least, from Elon opening his mouth too wide and Uber (UBER)/Lyft (LYFT) fighting NYC on new rideshare app regulations. All in all, last week presented us with a chance to look at an NYC taxi medallion chart - who wudda ever thought? Anyway, regulations were signed into law last week by NYC mayor de Blasio, limiting the number of ridesharing app licenses, as well as requiring a minimum pay for its drivers of $17.

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 784635104